Evidence map›Paper›PMID 26375285›Full record

ArticlePloS one2015

The Green Tea Component (-)-Epigallocatechin-3-Gallate Sensitizes Primary Endothelial Cells to Arsenite-Induced Apoptosis by Decreasing c-Jun N-Terminal Kinase-Mediated Catalase Activity.

Jee-Youn Kim, Ji-Young Choi, Hyeon-Ju Lee, Catherine Jeonghae Byun, Jung-Hyun Park, Jae Hoon Park, Ho-Seong Cho, Sung-Jin Cho, Sangmee Ahn Jo, Inho Jo

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Therapeutic properties of green tea against environmental insults.The Journal of nutritional biochemistry · 2017
    Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Jee-Youn KimDepartment of Molecular Medicine, Ewha Womans University School of medicine, Seoul, South Korea; Department of Radiation Oncology, College of Medicine, Yonsei University, Seoul, South Korea.
Ji-Young ChoiDepartment of Molecular Medicine, Ewha Womans University School of medicine, Seoul, South Korea; Department of Nanobiomedical Science & BK21 PLUS NBM Global Research Center for Regenerative Medicine, Dankook University, Cheonan, Chungnam, South Korea.
Hyeon-Ju LeeDepartment of Molecular Medicine, Ewha Womans University School of medicine, Seoul, South Korea.
Catherine Jeonghae ByunDepartment of Molecular Medicine, Ewha Womans University School of medicine, Seoul, South Korea.
Jung-Hyun ParkDepartment of Molecular Medicine, Ewha Womans University School of medicine, Seoul, South Korea.
Jae Hoon ParkDepartment of Pathology, College of Medicine, Kyung Hee University, Seoul, South Korea.
Ho-Seong ChoBiosafety Research Institute and College of Veterinary Medicine, Chonbuk National University, Jeonju, Chonbuk, South Korea.
Sung-Jin ChoDepartment of Biology, College of Natural Sciences, Chungbuk National University, Cheongju, South Korea.
Sangmee Ahn JoDepartment of Nanobiomedical Science & BK21 PLUS NBM Global Research Center for Regenerative Medicine, Dankook University, Cheonan, Chungnam, South Korea; Department of Pharmacology, College of Pharmacy, Dankook University, Cheonan, Chungnam, South Korea.
Inho JoDepartment of Molecular Medicine, Ewha Womans University School of medicine, Seoul, South Korea.
Ewha Womans University · KRKyung Hee University · KRChungbuk National University · KRDankook University · KRJeonbuk National University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The green tea component (-)-epigallocatechin-3-gallate (EGCG) has been shown to sensitize many different types of cancer cells to anticancer drug-induced apoptosis, although it protects against non-cancerous primary cells against toxicity from certain conditions such as exposure to arsenic (As) or ultraviolet irradiation. Here, we found that EGCG promotes As-induced toxicity of primary-cultured bovine aortic endothelial cells (BAEC) at doses in which treatment with each chemical alone had no such effect. Increased cell toxicity was accompanied by an increased condensed chromatin pattern and fragmented nuclei, cleaved poly(ADP-ribose) polymerase (PARP), activity of the pro-apoptotic enzymes caspases 3, 8 and 9, and Bax translocation into mitochondria, suggesting the involvement of an apoptotic signaling pathway. Fluorescence activated cell sorting analysis revealed that compared with EGCG or As alone, combined EGCG and As (EGCG/As) treatment significantly induced production of reactive oxygen species (ROS), which was accompanied by decreased catalase activity and increased lipid peroxidation. Pretreatment with N-acetyl-L-cysteine or catalase reversed EGCG/As-induced caspase activation and EC toxicity. EGCG/As also increased the phosphorylation of c-Jun N-terminal kinase (JNK), which was not reversed by catalase. However, pretreatment with the JNK inhibitor SP600125 reversed all of the observed effects of EGCG/As, suggesting that JNK may be the most upstream protein examined in this study. Finally, we also found that all the observed effects by EGCG/As are true for other types of EC tested. In conclusion, this is firstly to show that EGCG sensitizes non-cancerous EC to As-induced toxicity through ROS-mediated apoptosis, which was attributed at least in part to a JNK-activated decrease in catalase activity.

Indexed as

AnimalsAntioxidantsAortaArsenitesBlotting, WesternCatalaseCatechinCattleCells, CulturedDrug ResistanceDrug SynergismEndothelium, VascularHumansImmunoenzyme TechniquesJNK Mitogen-Activated Protein KinasesMitochondriaAntioxidantsarseniteArsenitesCatalaseCatechinepigallocatechin gallateJNK Mitogen-Activated Protein KinasesReactive Oxygen SpeciesTeaTeratogens

Identifiers

PMID26375285
PMCPMC4574201
OpenAlexW2173687139

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.